Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Verona Pharma has agreed a new $400 million debt facility ... its therapy for chronic obstructive pulmonary disease (COPD). The Anglo-US company has already tapped $50 million of the funding ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

dual inhibitor of PDE3 and PDE4 in a broad COPD populationLONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company ...

Citing preliminary unaudited results on Tuesday, Verona Pharma (NASDAQ ... for adults with chronic obstructive pulmonary disease (COPD) in June, and the company launched the product in August.

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the ...

GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary ...

To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1- Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD ...